The presentation exceeded all my expectations: clinical signs of efficacy; P21 activation ; no serious side effects; Phase 1 trial progressing to 5th cohort; uplisting without a reverse split plus the kicker of an inexpensive acquisition with promising drugs.
I think the the share price today is a product of the buying of the IHUB posters and lurkers.
Tomorrow we will see new buyers with deeper pockets.